Biomarkers for prostate cancer

Danil V. Makarov; Stacy Loeb; Robert H. Getzenberg; Alan W. Partin

doi:10.1146/annurev.med.60.042307.110714

Biomarkers for prostate cancer

Danil V. Makarov, Stacy Loeb, Robert H. Getzenberg, Alan W. Partin

School of Medicine

Research output: Contribution to journal › Review article › peer-review

149 Scopus citations

Abstract

The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.

Original language	English (US)
Pages (from-to)	139-151
Number of pages	13
Journal	Annual review of medicine
Volume	60
DOIs	https://doi.org/10.1146/annurev.med.60.042307.110714
State	Published - Jul 24 2009

Keywords

Blood test
Prostate biopsy
Prostate-specific antigen (PSA)
Radical prostatectomy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1146/annurev.med.60.042307.110714

Cite this

@article{84f6d58150e9424383e001f4c0f9c406,

title = "Biomarkers for prostate cancer",

abstract = "The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.",

keywords = "Blood test, Prostate biopsy, Prostate-specific antigen (PSA), Radical prostatectomy",

author = "Makarov, {Danil V.} and Stacy Loeb and Getzenberg, {Robert H.} and Partin, {Alan W.}",

year = "2009",

month = jul,

day = "24",

doi = "10.1146/annurev.med.60.042307.110714",

language = "English (US)",

volume = "60",

pages = "139--151",

journal = "Annual review of medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Biomarkers for prostate cancer

AU - Makarov, Danil V.

AU - Loeb, Stacy

AU - Getzenberg, Robert H.

AU - Partin, Alan W.

PY - 2009/7/24

Y1 - 2009/7/24

N2 - The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.

AB - The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.

KW - Blood test

KW - Prostate biopsy

KW - Prostate-specific antigen (PSA)

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=65949096925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949096925&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.60.042307.110714

DO - 10.1146/annurev.med.60.042307.110714

M3 - Review article

C2 - 18947298

AN - SCOPUS:65949096925

SN - 0066-4219

VL - 60

SP - 139

EP - 151

JO - Annual review of medicine

JF - Annual review of medicine

ER -

Biomarkers for prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this